Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556242 | 0.83 | CYP3A4 (0.33) | L3MBTL1POLBCYP1A2ASAH1 | |
| SCHEMBL1555372 | 0.80 | TSHR (0.41) | POLBCNR2RECQLCYP1A2ASAH1 | |
| SCHEMBL1556843 | 0.78 | CNR1 (0.39) | POLBCNR2RECQLCYP1A2ASAH1 | |
| SCHEMBL7716898 | 0.77 | EPHX1 (0.42) | L3MBTL1POLBCYP1A2 | |
| SCHEMBL2876205 | 0.72 | — | — | |
| SCHEMBL1555324 | 0.72 | — | — | |
| SCHEMBL24985018 | 0.70 | — | — | |
| SCHEMBL11200039 | 0.70 | — | — | |
| SCHEMBL4463879 | 0.70 | — | — | |
| SCHEMBL8695856 | 0.70 | HPGD (0.40) | L3MBTL1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | claimed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-109563515-A | Compound and the method for adjusting RNA function | 阿拉基斯医疗公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7772190-B2 | Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same | BAYER ANIMAL HEALTH GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-0871630-A1 | 4a,5a,8a,8b-TETRAHYDRO-6H-PYRROLO 3,4':4,5]FURO(3,2-b)PYRIDINE-6,8 7H]-DIONE DERIVATIVES FOR USE IN CONTROLLING ENDOPARASITES AND A METHOD OF PRODUCING SAID DERIVATIVES | BAYER AG (DE) | 1998-10-21 | — | — | EP | disclosed |
| US-5763453-A | ANTITUMOR AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0843658-A1 | DIDEPSIPEPTIDE-BASED ENDOPARASITICIDES, NEW DIDEPSIPEPTIDES AND PROCESS FOR PREPARING THE SAME | BAYER AG (DE) | 1998-05-27 | — | — | EP | disclosed |
| US-5733918-A | ANTITUMOR AGENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| US-5710162-A | ANTITUMOR AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
| EP-0785191-A1 | FUSED INDAN DERIVATIVES AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997014695-A1 | 4a,5a,8a,8b-TETRAHYDRO-6H-PYRROLO[3,4':4,5]FURO(3,2-b)PYRIDINE-6,8[7H]-DIONE DERIVATIVES FOR USE IN CONTROLLING ENDOPARASITES AND A METHOD OF PRODUCING SAID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-24 | — | — | WO | disclosed |
| WO-1997007093-A1 | DIDEPSIPEPTIDE-BASED ENDOPARASITICIDES, NEW DIDEPSIPEPTIDES AND PROCESS FOR PREPARING THE SAME | BAYER AKTIENGESELLSCHAFT (DE) | 1997-02-27 | — | — | WO | disclosed |
| EP-0713870-A1 | NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-05-29 | — | — | EP | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | L3MBTL1 4402/4885POLB 4780/4885CNR2 224/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | L3MBTL1 4402/4885POLB 4780/4885CNR2 224/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | L3MBTL1 4402/4885POLB 4780/4885CNR2 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.